Medivation, Inc. (MDVN):企業概要、財務及び戦略的SWOT分析

【英語タイトル】Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH66457FSA)・商品コード:GDPH66457FSA
・発行会社(調査会社):GlobalData
・発行日:2014年10月28日
・ページ数:55
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:アメリカ
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥14,125見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD375 ⇒換算¥42,375見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Medivation, Inc. (MDVN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Medivation, Inc. (Medivation), formerly Orion Acquisition Corp. II, is a biopharmaceutical company. It identifies, develops and markets therapies to treat serious diseases with unmet medical needs. The company’s product portfolio includes Xtandi, a drug indicated for the second-line treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Medivation entered into collaboration with Astellas Pharma Inc. for the development of its product candidate. Its pipeline includes Xtandi for indications such as chemotherapy naive metastatic prostate cancer and for estrogen/progesterone receptor positive and HER2 normal breast cancer. The company develops technologies which have ability to treat one or more serious diseases with unmet or limited medical needs. It operates along with its subsidiaries in the US and in the UK. Medivation is headquartered in San Francisco, California, the US.

Medivation, Inc. Key Recent Developments

Aug 07, 2014: Medivation Reports Second Quarter Financial Results and Provides Corporate Update
Jul 10, 2014: Medivation Announces Change in Executive Management Team
May 08, 2014: Medivation Reports First Quarter Financial Results and Provides Corporate Update
Apr 17, 2014: Medivation Appoints Patrick Machado to Board of Directors
Mar 31, 2014: Medivation Names Rick Bierly Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 – About the Company 6
Medivation, Inc. – Key Facts 6
Medivation, Inc. – Key Employees 7
Medivation, Inc. – Key Employee Biographies 8
Medivation, Inc. – Major Products and Services 9
Medivation, Inc. – Pharmaceutical Pipeline Products Data 10
Medivation, Inc., Pipeline Products by Therapy Area 10
Medivation, Inc., Pipeline Products by Development Phase 11
Medivation, Inc. – History 13
Medivation, Inc. – Company Statement 16
Medivation, Inc. – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Section 2 – Company Analysis 21
Medivation, Inc. – Business Description 21
Medivation, Inc. – Corporate Strategy 22
Medivation, Inc. – SWOT Analysis 23
SWOT Analysis – Overview 23
Medivation, Inc. – Strengths 23
Strength – Collaboration 23
Strength – First Approved Product of its Kind 23
Strength – Research and Development 24
Medivation, Inc. – Weaknesses 25
Weakness – Dependence on Third Party Manufacturers 25
Medivation, Inc. – Opportunities 26
Opportunity – Limited Therapies for mCRPC 26
Opportunity – License Agreement with OncoFusion 26
Opportunity – Prostate Cancer Market 26
Medivation, Inc. – Threats 27
Threat – Competitive Environment 27
Threat – Stringent Government Regulations 27
Threat – Uncertain R&D outcomes 27
Medivation, Inc. – Key Competitors 28
Section 3 – Company Financial Ratios 29
Financial Ratios – Capital Market Ratios 29
Financial Ratios – Annual Ratios 30
Performance Chart 31
Financial Performance 31
Financial Ratios – Interim Ratios 32
Financial Ratios – Ratio Charts 33
Section 4 – Company’s Lifesciences Financial Deals and Alliances 34
Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 34
Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 35
Medivation, Inc., Recent Deals Summary 36
Section 5 – Company’s Recent Developments 37
Aug 07, 2014: Medivation Reports Second Quarter Financial Results and Provides Corporate Update 37
Jul 10, 2014: Medivation Announces Change in Executive Management Team 38
May 08, 2014: Medivation Reports First Quarter Financial Results and Provides Corporate Update 39
Apr 17, 2014: Medivation Appoints Patrick Machado to Board of Directors 42
Mar 31, 2014: Medivation Names Rick Bierly Chief Financial Officer 43
Feb 27, 2014: Medivation Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update 44
Jan 06, 2014: Medivation Announces Participation at Upcoming Investor Conference 46
Nov 12, 2013: Medivation Reports Third Quarter Financial Results and Provides Corporate Update 47
Oct 30, 2013: Medivation Announces Participation at Upcoming Investor Conferences 49
Oct 28, 2013: Medivation Announces Third Quarter 2013 Financial Results Teleconference on November 12, 2013 50
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Medivation, Inc., Key Facts 6
Medivation, Inc., Key Employees 7
Medivation, Inc., Key Employee Biographies 8
Medivation, Inc., Major Products and Services 9
Medivation, Inc., Number of Pipeline Products by Therapy Area 10
Medivation, Inc., Number of Pipeline Products by Development Stage 11
Medivation, Inc., Pipeline Products By Therapy Area and Development Phase 12
Medivation, Inc., History 13
Medivation, Inc., Subsidiaries 20
Medivation, Inc., Key Competitors 28
Medivation, Inc., Ratios based on current share price 29
Medivation, Inc., Annual Ratios 30
Medivation, Inc., Interim Ratios 32
Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 34
Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 35
Medivation, Inc., Recent Deals Summary 36
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54

List of Figures
Medivation, Inc., Pipeline Products by Therapy Area 10
Medivation, Inc., Pipeline Products by Development Phase 11
Medivation, Inc., Performance Chart (2009 - 2013) 31
Medivation, Inc., Ratio Charts 33
Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 34
Medivation, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 35

★調査レポート[Medivation, Inc. (MDVN):企業概要、財務及び戦略的SWOT分析] (コード:GDPH66457FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[Medivation, Inc. (MDVN):企業概要、財務及び戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆